Addressing Gaps in ctDNA Testing

Opinion
Video

Medical professionals analyze gaps in current colorectal cancer patient care, with a focus on minimal residual disease testing.

  1. What gaps remain in our current understanding and application of MRD testing for CRC?
Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
4 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
4 experts are featured in this series.
Related Content
Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer

Encorafenib Combo Improves PFS in Metastatic Colorectal Cancer

Tim Cortese
February 3rd 2025
Article

Full progression-free survival results for patients with BRAF V600E mCRC from the phase 3 BREAKWATER trial will be presented at an upcoming medical conference.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.

First-Line Serplulimab Plus HLX04 Shows Manageable Safety in Advanced HCC

Roman Fabbricatore
January 30th 2025
Article

Results from a phase 2 trial revealed serplulimab plus HLX04 elicited promising antitumor activity in patients with advanced hepatocellular carcinoma.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Ensuring Quality Rectal Cancer Surgery at NAPRC-Accredited Institutions

Steven Wexner, MD, PhD;Arielle Kanters, MD
May 27th 2024
Podcast

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Positive Responses Demonstrated by Adagrasib and Cetuximab in KRAS G12C-Mutant mCRC

Positive Responses Demonstrated by Adagrasib and Cetuximab in KRAS G12C-Mutant mCRC

Ashley Chan
January 27th 2025
Article

At a longer follow-up, adagrasib with cetuximab maintained meaningful efficacy and elicited an ORR of 34%, results from the phase 1/2 KRYSTAL-1 showed.

Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.

Fruquintinib Combo Shows Activity in Pretreated Metastatic CRC

Jax DiEugenio
January 27th 2025
Article

Phase 2 data may support fruquintinib plus TAS-102 as an alternative third-line treatment in patients with metastatic colorectal cancer.